Post-operative AICS status in completely resected lung cancer patients with pre-operative AICS abnormalities: predictive significance of disease recurrence

Takashi Anayama1, Masahiko Higashiyama2, Hiroshi Yamamoto3, Shinya Kikuchi3, Atsuko Ikeda4, Jiro Okami2, Toshiteru Tokunaga2, Kentaro Hirohashi1, Ryohei Miyazaki1 & Kazumasa Orihashi1

The AminoIndex™ Cancer Screening (AICS) system, a plasma-free amino acid (PFAA)-based multivariate discrimination index, is a blood screening test for lung cancer based on the comparison of PFAA concentrations between patients with lung cancer and healthy controls. Pre- and post-operative AICS values were compared among 72 patients who underwent curative resection for lung cancer. Post-operative changes in PFAA concentrations were also evaluated. AICS values were classified as rank A (0.0–4.9), B (5.0–7.9), or C (8.0–10.0). Rank B–C patients were evaluated for outcomes and post-operative changes in their AICS values. Twenty-three of the 44 pre-operative rank B–C patients experienced post-operative reductions in AICS rank. Only one patient experienced cancer recurrence. Post-operative changes in PFAA concentrations were associated with the risk of post-operative cancer recurrence ($p = 0.001$). Multivariate analysis revealed that the absence of a post-operative reduction in AICS rank independently predicted cancer recurrence (hazard ratio: 14.28; $p = 0.012$). The majority of patients had high pre-operative AICS values and exhibited a reduction in AICS rank after curative resection. However, the absence of a post-operative reduction in AICS rank was associated with cancer recurrence, suggesting that AICS rank may be a sensitive marker of post-operative recurrence.

Lung cancer is a leading cause of global morbidity and mortality, with approximately 14 million new cases in 20121. Early detection and monitoring are important for improving treatment outcomes. Several serological markers (e.g., carcinoembryonic antigen [CEA] for adenocarcinoma and cytokeratin 19 fragment [CYFRA] for squamous cell carcinoma) have been used clinically for diagnostic and prognostic prediction and monitoring disease progression, recurrence, and response to treatment2. However, these tumour markers are not always elevated in the early stages of cancer development3. Therefore, the screening, diagnosis, and treatment of non-small-cell lung cancer could theoretically be improved by using a sensitive biomarker that can identify lung cancer and predict recurrence at an early stage.

Plasma-free amino acid (PFAA) concentrations are usually controlled at a constant ratio by homeostatic mechanisms. However, the balance of PFAA concentrations can vary in different diseases, including various cancers, liver or renal failure, and Alzheimer’s disease4–6. Therefore, we developed the AminoIndex™ technology, which scores health conditions and the possibility of disease using multivariate analysis with PFAA concentrations included as a variable4–6. By comparing and analysing the ratios of 19 genetically encoded PFAAs in plasma samples derived from approximately 2,500 patients with cancer and approximately 15,000 healthy controls, we found that the PFAA concentration ratio was altered in 7 types of cancer, including lung cancer7–16. These findings...
 allowed us to develop and clinically implement the AminoIndex™ Cancer Screening (AICS) system as an early screening test\textsuperscript{10}. The lung-specific AICS (AICS \textsubscript{lung}) system identifies lung cancer based on the plasma concentrations of six statistically significant amino acids (serine, glutamine, alanine, histidine, ornithine, and lysine) and has been used to screen for lung cancer in Japan\textsuperscript{10,11}. Based on the PFAA profile, the probability of lung cancer is expressed as AICS \textsubscript{lung} values of 0.0–10.0, which are categorised as rank A (0.0–4.9), B (5.0–7.9), and C (8.0–10.0)\textsuperscript{10}. Higher AICS \textsubscript{lung} values are associated with an increased risk of lung cancer\textsuperscript{10}.

Although AICS scores reflect PFAA concentrations, it is unclear whether these changes are related to the cancer itself or the underlying cause. The causal relationship between lung cancer and changes in PFAA concentrations has yet to be elucidated. For instance, if a high pre-operative AICS value is reduced to a lower AICS value after curative resection, it is possible that the index might reflect the presence of lung cancer and be a useful screening marker. Therefore, the present study aimed to evaluate post-operative changes in AICS \textsubscript{lung} values among patients who underwent curative resection for lung cancer, as well as the association of these changes with post-operative cancer recurrence. Our findings suggest that the pre- and post-operative PFAA profile may be a useful screening marker for lung cancer.

### Results

#### Patient characteristics.
Patient characteristics according to pre-operative AICS \textsubscript{lung} rank are shown in Table 1. The AICS \textsubscript{lung} rank was rank A in 28 patients (38.9%), rank B in 15 patients (20.8%), and rank C in 29 patients (40.3%). Forty-four patients (61.1%) had high pre-operative AICS \textsubscript{lung} values (rank B–C). No significant differences in rank were observed according to age, sex, pathological stage (pStage), tissue type, or treatment. Pre-operative AICS \textsubscript{lung} rank was associated with the degree of cancer differentiation, with rank C more frequently observed among patients with poorly differentiated cancer.

| Characteristic | Pre-operative AICS \textsubscript{lung} | | | | | p-value* |
|---------------|---------------------------------|---|---|---|---|
| All \( (n = 72) \) | Rank A \( (n = 28) \) | Rank B \( (n = 15) \) | Rank C \( (n = 29) \) | | |
| Age (years) | | | | | 0.314 |
| Median (IQR) | 64 (58–72) | 59 (55–72) | 65 (61–74) | 64 (58–72) | |
| Range | 34–79 | 34–77 | 35–78 | 44–79 | |
| Sex, n (%) | | | | | 0.822 |
| Male | 41 (56.9) | 15 (53.6) | 8 (53.3) | 18 (62.1) | |
| Female | 31 (43.1) | 13 (46.4) | 7 (46.7) | 11 (37.9) | |
| pStage, n (%) | | | | | 0.070 |
| 0 | 4 (5.6) | 3 (10.7) | 0 (0.0) | 1 (3.4) | |
| I | 47 (65.3) | 22 (78.6) | 11 (73.3) | 14 (48.3) | |
| II | 10 (13.9) | 1 (3.6) | 3 (20.0) | 6 (20.7) | |
| III | 10 (13.9) | 2 (7.1) | 1 (6.7) | 7 (24.1) | |
| IV | 1 (1.4) | 0 (0.0) | 0 (0.0) | 1 (3.4) | |
| Histological type, n (%) | | | | | 0.112 |
| ADC | 57 (79.2) | 23 (82.1) | 13 (86.7) | 21 (72.4) | |
| SqCC | 11 (15.3) | 5 (17.9) | 0 (0.0) | 6 (20.7) | |
| Other | 4 (5.6) | 0 (0.0) | 2 (13.3) | 2 (6.9) | |
| Differentiation, n (%) | | | | | 0.005 |
| Well | 25 (34.7) | 16 (57.1) | 5 (33.3) | 4 (13.8) | |
| Moderate | 35 (48.6) | 10 (35.7) | 9 (60.0) | 16 (55.2) | |
| Poor | 10 (13.9) | 1 (3.6) | 1 (6.7) | 8 (27.6) | |
| Unknown | 2 (2.8) | 1 (3.6) | 0 (0.0) | 1 (3.4) | |
| Treatment, n (%) | | | | | 0.817 |
| S | 62 (86.1) | 25 (89.3) | 13 (86.7) | 24 (82.8) | |
| S + ACT | 8 (11.1) | 2 (7.1) | 2 (13.3) | 4 (13.8) | |
| S + ART | 1 (1.4) | 1 (3.6) | 0 (0.0) | 0 (0.0) | |
| S + ACT/ART | 1 (1.4) | 0 (0.0) | 0 (0.0) | 1 (3.4) | |

Table 1. Patient demographics. *p-values calculated using the Kruskal-Wallis test for comparisons of medians, or Fisher's exact test for comparisons of rank. Abbreviations: ACT, adjuvant chemotherapy; ADC, adenocarcinoma; AICS \textsubscript{lung}, lung-specific AminoIndex™ Cancer Screening; ART, adjuvant radiotherapy; IQR, interquartile range; p-Stage, pathological stage; S, surgery; SqCC, squamous cell carcinoma.

### Results

#### Patient characteristics.
Patient characteristics according to pre-operative AICS \textsubscript{lung} rank are shown in Table 1. The AICS \textsubscript{lung} rank was rank A in 28 patients (38.9%), rank B in 15 patients (20.8%), and rank C in 29 patients (40.3%). Forty-four patients (61.1%) had high pre-operative AICS \textsubscript{lung} values (rank B–C). No significant differences in rank were observed according to age, sex, pathological stage (pStage), tissue type, or treatment. Pre-operative AICS \textsubscript{lung} rank was associated with the degree of cancer differentiation, with rank C more frequently observed among patients with poorly differentiated cancer.

#### Pre-operative positive ratios.
Pre-operative positive ratios of CEA, CYFRA, and AICS \textsubscript{lung} are shown in Table 2. Among 72 patients, 44 had an AICS \textsubscript{lung} rank of B–C. The sensitivity of AICS \textsubscript{lung} rank B–C, CEA, and CYFRA was 61.1%, 15.9%, and 5.3%, respectively. CEA was considerably higher in adenocarcinomas and CYFRA was considerably higher in squamous cell carcinomas.
Comparison of AICS (lung) rank before and after curative resection. Post-operative changes in AICS (lung) rank were examined in 44 patients with a pre-operative AICS (lung) rank of B–C. After curative resection, the AICS (lung) rank was reduced to rank A–B in 23 patients (52.3%). Changes in AICS (lung) rank after curative resection according to whether the patient experienced recurrence or not are shown in Fig. 1a,b. Among 23 patients with a post-operative reduction in AICS (lung) rank, only one (4.3%) experienced post-operative recurrence. Among 21 patients with no post-operative reduction in AICS (lung) rank, 11 (52.4%) experienced post-operative recurrence.

Among 29 patients with a pre-operative AICS (lung) rank of C, 14 (48.3%) experienced a post-operative reduction in rank, with only one patient (7.1%) experiencing recurrence. In contrast, 11 (73.3%) of 15 patients without a post-operative reduction in AICS (lung) rank experienced recurrence. The absence of a post-operative reduction in AICS (lung) rank was associated with cancer recurrence (Table 3).

Univariate and multivariate analysis of six factors (age, sex, pStage, histological type, cancer differentiation, and a post-operative reduction in AICS (lung) rank) revealed that the absence of a post-operative reduction in AICS (lung) rank (hazard ratio: 14.28; \( p = 0.012 \)) and pStage II–IV disease (hazard ratio: 4.58; \( p = 0.024 \)) were independent predictors of cancer recurrence (Table 4).

Changes in PFIAA concentrations after curative resection. Pre- and post-operative plasma concentrations of serine, glutamine, alanine, histidine, ornithine, and lysine are shown in Fig. 2a–c. Patients who did not experience recurrence had similar post-operative PFIAA concentrations compared to healthy controls. Patients who experienced recurrence did not have any noticeable change in post-operative PFIAA concentrations compared to pre-operative PFIAA concentrations.

Disease-free survival by post-operative AICS (lung) rank status. For the 44 patients who were AICS (lung) rank B–C before surgery, the disease-free survival (DFS) was compared using Kaplan-Meier survival curves (Fig. 3). The group that maintained rank B–C after surgery had significantly worse DFS compared to the group with reduced AICS (lung) rank after surgery (\( p < 0.001 \)).

Table 2. Pre-operative serum CEA, CYFRA, and AICS (lung) rank in patients with non-small-cell lung cancer. *B–C vs. A. Abbreviations: ADC, adenocarcinoma; AICS (lung), lung-specific AminoIndex™ Cancer Screening; CEA, carcinoembryonic antigen; CYFRA, cytokeratin 19 fragment; SqCC, squamous cell carcinoma.

|                | CEA (n = 69) high/normal (sensitivity, %) | CYFRA (n = 57) high/normal (sensitivity, %) | AICS (lung) (n = 72) rank C/B/A (sensitivity, %)* |
|----------------|------------------------------------------|--------------------------------------------|--------------------------------------------------|
| ALL            | 11/58 (15.9)                             | 3/54 (5.3)                                 | 29/15/28 (61.1)                                  |
| ADC            | 9/46 (16.4)                              | 2/42 (4.5)                                 | 21/13/23 (59.6)                                  |
| SqCC           | 1/9 (10.0)                               | 1/9 (10.0)                                 | 6/0/5 (54.5)                                    |
| Other          | 1/3 (25.0)                               | 0/3 (0.0)                                  | 2/2/0 (100.0)                                   |

Figure 1. Post-operative changes in AICS (lung) values. Paired pre- and post-operative AICS (lung) values are shown for patients with a pre-operative AICS (lung) rank of (a) B and (b) C. The dotted line shows that a cut-off AICS (lung) value of 5.0 produces a specificity of 80.0%. Abbreviations: AICS (lung), lung-specific AminoIndex™ Cancer Screening; pre-op., pre-operative; post-op., post-operative. ***Wilcoxon signed-rank, \( p < 0.001 \).

*a vs. b, \( p < 0.001 \).
Table 3. Changes in AICS (lung) rank after curative resection among patients with a pre-operative AICS (lung) rank of B–C. *p*-values calculated using Fisher’s exact test, n (%). Abbreviations: AICS (lung), lung-specific AminoIndex™ Cancer Screening.

Table 4. Univariate and multivariate analysis. Abbreviations: ADC, adenocarcinoma; AICS (lung), lung-specific AminoIndex™ Cancer Screening; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; mod., moderate; pStage, pathological Stage.

Discussion
In this study, we evaluated post-operative changes in AICS (lung) rank among patients who underwent curative resection for lung cancer. A pre-operative AICS (lung) rank of B–C was observed in 44 (61.1%) of 72 patients. A high rank was more frequently observed among patients with poorly differentiated cancer. In this context, lung cancer has diverse histological types and subtypes, with well-differentiated adenocarcinomas exhibiting non-invasive slow proliferation with lepidic growth that does not destroy the alveolar structure. Thus, recurrence is rare if well-differentiated adenocarcinomas are completely resected. However, poorly differentiated lung cancer is highly malignant and is associated with a poor prognosis. Therefore, the high AICS (lung) rank among patients with poorly differentiated lung cancer may reflect its biological malignancy, although large-scale studies are needed to clarify the relationship between histological classification and AICS (lung) rank.

Surgical resection was associated with a reduction in post-operative AICS (lung) rank (C to A–B or B to A) in 23 (52.3%) of the 44 patients with a pre-operative AICS (lung) rank of B–C. Furthermore, 22 (95.7%) of the 23 patients experienced disease-free survival after curative resection, while 11 (52.4%) of the 21 patients with no post-operative change in AICS (lung) rank experienced post-operative recurrence. There was also a significant difference in DFS, as shown in Kaplan-Meier survival curve analysis based on post-operative changes in AICS (lung) rank. Moreover, the multivariate analysis revealed that the absence of a post-operative reduction in AICS (lung) rank and pStage II–IV disease were independent predictors of cancer recurrence after curative resection. It is possible that post-operative AICS (lung) rank accurately reflects the presence of residual lung cancer cells that were not detected during resection. Therefore, AICS (lung) rank may represent a sensitive tumour marker that can predict post-operative recurrence.

Of the six amino acids that are included in the AICS (lung) formula, the concentrations of serine, glutamine, ornithine, and lysine in patients without post-operative recurrence were similar to those of healthy controls. Thus, it appears that these amino acids reflect the presence of residual cancer cells. It has recently been suggested that cancer cells indirectly affect the amino acid metabolism of distant organs and alter the PFAA profile. However, there was no significant change in the post-operative concentration of alanine compared to its pre-operative concentration. Thus, although alanine is included in the AICS (lung) system to differentiate between patients with cancer and healthy controls, it is possible that the concentration of alanine may reflect predisposing background factors, such as the patient’s constitution and lifestyle, rather than the presence or absence of lung cancer. Given the uncertainty surrounding the mechanism by which cancer causes changes in the PFAA profile, further studies are needed to provide a more detailed analysis of the pre- and post-operative concentrations of each amino acid.

There is a limitation to this study. The 10 patients who had a pre-operative AICS (lung) rank of B–C and no post-operative reduction in AICS (lung) rank did not experience cancer recurrence during follow-up. However, long-term follow-up may be necessary to determine whether a high post-operative AICS (lung) rank in these cases was a false positive or whether recurrent lesions will emerge in the future.
A high pre-operative AICS (lung) rank and the absence of a post-operative reduction in AICS (lung) rank are risk factors for recurrence. AICS (lung) rank may be a sensitive marker of post-operative recurrence in patients with lung cancer.

Methods

Ethical considerations. This prospective observational study was performed in accordance with the Declaration of Helsinki, and the study protocol was approved by the Ethics Committees of the Osaka International Cancer Institute (Osaka, Japan) (formerly the Osaka Medical Center for Cancer and Cardiovascular Diseases) (ERB-000486) and the Kochi University School of Medicine (Kochi, Japan) (ERB-000137). All participants gave their written informed consent for inclusion in this study. All data were analysed anonymously.

Patient recruitment. Patients who underwent curative resection for primary lung cancer at the Osaka International Cancer Institute (Osaka, Japan) or Kochi University School of Medicine (Kochi, Japan) between

Figure 2. Radar charts of AICS (lung) amino acid concentrations among patients with a pre-operative AICS (lung) rank of B–C. Receiver operating characteristic curve analysis was performed for six amino acids. Areas under the receiver operating characteristic curves were used to determine whether each amino acid could discriminate between patients with lung cancer and healthy controls. (a) Patients with a pre-operative AICS (lung) rank of B–C who did not experience recurrence. (b) Patients with a pre-operative AICS (lung) rank of C who did not experience recurrence. (c) Patients with a pre-operative AICS (lung) rank of B–C who did experience recurrence. Only minor changes in post-operative amino acid concentrations were observed. Black bold lines indicate points where the area under the receiver operating characteristic curve was 0.5. Abbreviations: AICS (lung), lung-specific AminoIndex™ Cancer Screening.

Figure 3. Disease-free survival of patients with a pre-operative AICS (lung) rank of B–C. Kaplan-Meier survival estimates of patients with or without AICS (lung) rank reduction. A log-rank test was used to test the significance, and censored patients are indicated by crosses. Abbreviations: AICS (lung), lung-specific AminoIndex™ Cancer Screening.
January 2007 and December 2010 were enrolled. Patients underwent pre-operative blood sampling within 1 week prior to surgery and post-operative blood sampling 0.7–5.5 years after surgery. The median follow-up time was 7.1 (range, 1.7–8.7) years. Patients were excluded if they had a history of other malignancies. Tumours were classified according to the American Joint Committee on Cancer and Union for International Cancer Control Lung Cancer Stage Classification (8th edition)30. Histological classification and histological grading was performed according to the 8th21 and 7th22 editions of the TNM Classification of Malignant Tumors.

Measurements of PF AA concentrations. Blood samples (5.0 mL) were collected from a forearm vein on the morning after an overnight fasting, using tubes containing ethylenediaminetetraacetic acid, and were immediately placed on ice. Plasma was prepared by centrifugation at 3,000 rpm for 15 minutes at 4 °C and was stored at −80 °C until analysis. Plasma samples were deproteinised using acetonitrile at a final concentration of 80.0%. PF AA concentrations were measured using high-performance liquid chromatography/electrospray ionisation tandem mass spectrometry with pre-column derivatisation, which have been described previously23–25.

AICS (lung) values and ranks. AICS (lung) values for patients with lung cancer were classified as rank A, B, or C based on a previous report10. AICS (lung) detects lung cancer from plasma concentrations of serine, glutamine, alanine, histidine, ornithine, and lysine9,14. AICS (lung) values range between 0.0 and 10.0, with 5.0 producing 80.0% specificity and 8.0 producing 95.0% specificity. A high AICS (lung) value is associated with a greater probability of lung cancer. Rank A is considered to be normal (0.0–4.9), rank B is considered to be relatively high (5.0–7.9), and rank C is considered to be high (8.0–10.0).

Statistical analyses. Statistical analyses were performed using Fisher’s exact test or the Kruskal-Wallis test, as appropriate. Post-operative changes in AICS (lung) rank were evaluated using the Wilcoxon signed-rank test. Receiver operating characteristic curve analyses were performed to determine the abilities of PF AA concentrations and the post-operative AICS (lung) rank to differentiate between patients with lung cancer and healthy controls11. The 95.0% confidence intervals for the areas under the receiver operating characteristic curves were estimated based on the method described by Hanley and McNeil26. Multivariate analysis was performed using Cox regression model. Results were presented as hazard ratios and 95.0% confidence intervals. Survival curves were drawn by the Kaplan-Meier method, and a statistical evaluation of the curves was performed using a log-rank test. All statistical analyses were conducted using GraphPad Prism (software version 6; GraphPad Software Inc., San Diego, CA, USA) and R software (version 3.2.2; The R Foundation for Statistical Computing, Vienna, Austria).

Data availability. The datasets generated during and/or analysed during the current study are not publicly available due to the nature of the ethical approval of this study but are available to readers who meet the criteria for access to confidential data from the Ethics Committee of Kochi University School of Medicine (Kochi, Japan) (im32@kochi-u.ac.jp).

References
1. Asamura, H. et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J. Thorac. Oncol. 3, 46–52 (2008).
2. Duffy, M. I. Tumor markers in clinical practice: a review focusing on common solid cancers. Med. Prim. Pract. 22, 4–11 (2013).
3. Okamura, K. et al. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 80, 45–49 (2013).
4. Rosen, H. M., Yoshimura, N., Hodgman, J. M. & Fischer, J. E. Plasma amino acid patterns in hepatic encephalopathy of differing etiology. Gastroenterology 72, 483–487 (1977).
5. Suliman, M. E. et al. Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am. J. Clin. Nutr. 82, 342–349 (2005).
6. Ravaglia, G. et al. Plasma amino acid concentrations in patients with amnestic mild cognitive impairment or Alzheimer disease. Am. J. Clin. Nutr. 80, 483–488 (2004).
7. Noguchi, Y. et al. Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. Am. J. Clin. Nutr. 83, 513S–519S (2006).
8. Kimura, T., Noguchi, Y., Shikata, N. & Takahashi, M. Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks. Curr. Opin. Clin. Nutr. Metab. Care. 12, 49–53 (2009).
9. Maeda, T. et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non–small cell lung cancer: a case control study. BMC Cancer 10, 690 (2010).
10. Okamoto, N. Use of AminoIndex technology for cancer screening. Ningen Dock. 26, 911–922 (2012).
11. Miyagi, Y. et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 6, e24143 (2011).
12. Miura, T. et al. Potential of plasma amino acid profiles for use as novel diagnostic marker for prostate cancer. Ningen Dock. 26, 51–55 (2011).
13. Miyagi, E. et al. Diagnostic performance and clinical utility of novel gynecologic cancer screening method based on AminoIndex technology. Ningen Dock. 26, 749–755 (2011).
14. Shingyoji, M. et al. The significance and robustness of a plasma free amino acid (PF AA) profile-based multiplex function for detecting lung cancer. BMC Cancer. 13, 77 (2013).
15. Ihata, Y. et al. Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker. Int. J. Clin. Oncol. 19, 364–372 (2014).
16. Fukutake, N. et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS One. 10, e0132233 (2015).
17. Barletta, J. A., Yeap, B. Y. & Chirieac, L. R. Prognostic significance of grading in lung adenocarcinoma. Cancer. 116, 659–669 (2010).
18. Hung, J. J. et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann. Surg. 258, 1079–1086 (2013).
19. Luo, Y. et al. Cancer usurps skeletal muscle as an energy repository. Cancer Res. 74, 330–340 (2014).
Acknowledgements
We would like to thank Editage (www.editage.jp) for English language editing.

Author Contributions
T.A. wrote the manuscript. K.H., R.H., J.O., and T.T. collected the blood samples and the clinical data. H.Y., S.K., and A.I. measured the PFAA concentrations and calculated the AICS (lung) values. T.A. and S.K. prepared the figures. T.A., M.H., and K.O. conducted the clinical studies across the two institutes. All authors reviewed the manuscript.

Additional Information
Competing Interests: H.Y., S.K., and A.I. are employees of Ajinomoto Co., Inc. (Kanagawa, Japan). T.A. and M.H. have received research grants from Ajinomoto Co., Inc. (Kanagawa, Japan). This does not alter the authors’ adherence to the journal’s policies. The remaining authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018